P Y Lam

发表

Molecular Recognition of Cyclic Urea HIV-1 Protease Inhibitors*

Chong-Hwan Chang, PatrickY.-S. Lam, P. Jadhav, 1998, The Journal of Biological Chemistry.

Discovery of 1-[3-(aminomethyl)phenyl]-N-3-fluoro-2'-(methylsulfonyl)-[1,1'-biphenyl]-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC423), a highly potent, selective, and orally bioavailable inhibitor of blood coagulation factor Xa.

P. Lam, R. Knabb, R. Alexander, 2001, Journal of medicinal chemistry.

Improved cyclic urea inhibitors of the HIV-1 protease: synthesis, potency, resistance profile, human pharmacokinetics and X-ray crystal structure of DMP 450.

J L Meek, Chong-Hwan Chang, PatrickY.-S. Lam, 1996, Chemistry & biology.

Cyclic HIV protease inhibitors: synthesis, conformational analysis, P2/P2' structure-activity relationship, and molecular recognition of cyclic ureas.

Chong-Hwan Chang, P. Lam, P. Jadhav, 1996, Journal of medicinal chemistry.

Molecular basis of HIV-1 protease drug resistance: structural analysis of mutant proteases complexed with cyclic urea inhibitors.

P. Lam, C. Hodge, C. Chang, 1997, Biochemistry.

Counteracting HIV-1 protease drug resistance: structural analysis of mutant proteases complexed with XV638 and SD146, cyclic urea amides with broad specificities.

P. Lam, P. Jadhav, C. Chang, 1998, Biochemistry.

Cyclic HIV protease inhibitors: design and synthesis of orally bioavailable, pyrazole P2/P2' cyclic ureas with improved potency.

P. Lam, P. Jadhav, Y. Ru, 1998, Journal of medicinal chemistry.

Nonpeptide cyclic cyanoguanidines as HIV-1 protease inhibitors: synthesis, structure-activity relationships, and X-ray crystal structure studies.

J L Meek, P. Lam, P. Jadhav, 1998, Journal of medicinal chemistry.

De novo design and discovery of cyclic HIV protease inhibitors capable of displacing the active-site structural water molecule.

P K Jadhav, P Y Lam, B J Aungst, 1998, Pharmaceutical biotechnology.